Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

2020 Pipeline Insights on Complicated Urinary Tract Infections - ResearchAndMarkets.com

December 22, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Dec 22, 2020--

The “Complicated Urinary Tract Infections- Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Complicated Urinary Tract Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.



A good quality urine specimen is vital in making the diagnosis. However, treatment must not be delayed if the clinical scenario is strongly suggestive of a urinary tract infection. Blood cultures are also useful in more severe septic presentations. A positive blood culture can sometimes also help corroborate a urine sample result and reduce the suspicion of contamination. Ultrasound and CT scans may sometimes be useful or even critical for diagnosing perinephric abscess, urinary retention, hydronephrosis and obstructive pyelonephritis from stones in septic patients. All patients who fail to respond to appropriate broad-spectrum antibiotics should undergo imaging to exclude complications such as abscesses, urinary retention, calculi, gas, obstructive uropathy and hydronephrosis.


Resuscitation often precedes definitive treatment. The severely septic patient might need aggressive fluid resuscitation as well as broad-spectrum antibiotics administered in the emergency department. Antibiotic choice should always be according to local guidelines. Patients presenting with septic shock may not respond to fluid resuscitation alone, and there should be a low threshold to consider vasopressor support in light of a poor initial response to fluids.

Broad-spectrum, empiric antibiotics should always be switched to a targeted narrow-spectrum antibiotic, if possible, once culture results are available. Prophylactic antibiotics are seldom recommended due to rapid bacterial resistance patterns developing. When the clinical situation requires prophylaxis, nitrofurantoin is usually the preferred agent. Patients with permanent Foley catheters or suprapubic tubes should avoid prophylactic antibiotics and should only be treated when symptomatic. More frequent changes of urinary catheters is recommended in chronically cahteterized patients with recurrent infections.


Complicated Urinary Tract Infections Emerging Drugs

Tebipenem Pivoxil Hydrobromide: Spero Therapeutics

Tebipenem Pivoxil Hydrobromide is an oral carbapenem which acts as cell wall inhibitors. In September 2020, tebipenem HBr completed a pivotal Phase 3 trial, ADAPT-PO, for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval in the United States. Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of cUTI and AP.

Sulopenem: Iterum Therapeutics

Sulopenem, a novel penem anti-infective compound with oral and IV formulations is being developed for the treatment of complicated urinary tract infections has completed the pivotal phase 3 trail. The FDA has granted Special Protocol Agreements (SPA) and Qualified Infectious Disease Product (QIDP) designations for oral and IV sulopenem in accordance with the Generating Antibiotics Incentives Now (GAIN) Act, which allow for five years of additional regulatory exclusivity and expedited Fast Track FDA review.

Companies Mentioned

  • Spero Therapeutics
  • Iterum Therapeutics
  • Entasis Therapeutics
  • Locus Biosciences

Key Questions Answered

  • How many companies are developing Complicated Urinary Tract Infections drugs?
  • How many Complicated Urinary Tract Infections drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Complicated Urinary Tract Infections?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Complicated Urinary Tract Infections therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Complicated Urinary Tract Infections and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Complicated Urinary Tract Infections: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

4. Pipeline Therapeutics

  • Comparative Analysis

5. Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

6. Complicated Urinary Tract Infections- Analytical Perspective

7. In-depth Commercial Assessment

  • Complicated Urinary Tract Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends

8. Complicated Urinary Tract Infections Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

9. Late Stage Products (Phase III)

  • Comparative Analysis

10. Tebipenem pivoxil hydrobromide : Spero Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

11. Mid Stage Products (Phase II)

  • Comparative Analysis

12. Sulbactum: Entasis Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

13. Early Stage Products (Phase I)

  • Comparative Analysis

14. BPEC01: Locus Biosciences

  • Product Description
  • Research and Development
  • Product Development Activities

15. Pre-clinical and Discovery Stage Products

  • Comparative Analysis

16. LBPKP01: Locus Biosciences

  • Product Description
  • Research and Development
  • Product Development Activities

17. Inactive Products

  • Comparative Analysis

18. Complicated Urinary Tract Infections Key Companies

19. Complicated Urinary Tract Infections Key Products

20. Complicated Urinary Tract Infections- Unmet Needs

21. Complicated Urinary Tract Infections- Market Drivers and Barriers

22. Complicated Urinary Tract Infections- Future Perspectives and Conclusion

23. Complicated Urinary Tract Infections Analyst Views

24. Complicated Urinary Tract Infections Key Companies

25. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9j8qui

View source version on businesswire.com:https://www.businesswire.com/news/home/20201222005346/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 12/22/2020 07:50 AM/DISC: 12/22/2020 07:50 AM